Soluble guanylate cyclase activators and their use

A method for reducing elevated intraocular pressure in a human comprising administering to the human an effective amount of a compound according to Formula (I), or a pharmaceutically acceptable salt thereof:

• wherein:
• R1 is selected from H and —C1-3alkyl;
• R2 and R3 are each independently selected from H and halogen;
• R4 is selected from H, —C1-3alkyl, —O—C1-3alkyl, —O—C3-4cycloalkyl, —O—(CH2)p-oxetanyl, and —O—(CH2)p-tetrahydrofuranyl;
• X and Y are each CH;
• or if X is N, then Y is CH;
• or if Y is N then X is CH;
• A is absent or O;
• R5 is selected from —C1-4 alkyl, —C3-4 cycloalkyl, —(CH2)nCN, —(CH2)nCF3, —(CH2)m-tetrahydrofuranyl, —(CH2)m-oxetanyl, —C2-5 alkyl-OH, —C2-5 alkyl-OCH3 and —CO—R6;
• R6 is selected from —C1-6 alkyl and —C3-6 cycloalkyl, optionally substituted by —OH, —OCH3, —CN, COOH or —F, or R6 is —(CH2)m-tetrahydrofuranyl or —(CH2)m-oxetanyl, or R6 is a (CH2)m-4 to 5-membered heterocycle;
• n is 1 or 2;
• m is 0 or 1;
• and
• p is 0 or 1.

A method of treating glaucoma in a human comprising administering to the human an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof:

• wherein:
• R1 is selected from H and —C1-3alkyl;
• R2 and R3 are each independently selected from H and halogen;
• R4 is selected from H, —C1-3alkyl, —O—C1-3alkyl, —O—C3-4cycloalkyl, —O—(CH2)p-oxetanyl, and —O—(CH2)p-tetrahydrofuranyl;
• X and Y are each CH;
• or if X is N, then Y is CH;
• or if Y is N then X is CH;
• A is absent or O;
• R5 is selected from —C1-4 alkyl, —C3-4 cycloalkyl, —(CH2)nCN, —(CH2)nCF3, —(CH2)m-tetrahydrofuranyl, —(CH2)m-oxetanyl, —C2-5 alkyl-OH, —C2-5 alkyl-OCH3 and —CO—R6;
• R6 is selected from —C1-6 alkyl and —C3-6 cycloalkyl, optionally substituted by —OH, —OCH3, —CN, COOH or —F, or R6 is —(CH2)m-tetrahydrofuranyl or —(CH2)m-oxetanyl, or R6 is a (CH2)m-4 to 5-membered heterocycle;
• n is 1 or 2;
• m is 0 or 1;
• and
• p is 0 or 1.

A method of treating ocular hypertension in a human comprising administering to the human an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof:

• wherein:
• R1 is selected from H and —C1-3alkyl;
• R2 and R3 are each independently selected from H and halogen;
• R4 is selected from H, —C1-3alkyl, —O—C1-3alkyl, —O—C3-4cycloalkyl, —O—(CH2)p-oxetanyl, and —O—(CH2)p-tetrahydrofuranyl;
• X and Y are each CH;
• or if X is N, then Y is CH;
• or if Y is N then X is CH;
• A is absent or O;
• R5 is selected from —C1-4 alkyl, —C3-4 cycloalkyl, —(CH2)nCN, —(CH2)nCF3, —(CH2)m-tetrahydrofuranyl, —(CH2)m-oxetanyl, —C2-5 alkyl-OH, —C2-5 alkyl-OCH3 and —CO—R6;
• R6 is selected from —C1-6 alkyl and —C3-6 cycloalkyl, optionally substituted by —OH, —OCH3, —CN, COOH or —F, or R6 is —(CH2)m-tetrahydrofuranyl or —(CH2)m-oxetanyl, or R6 is a (CH2)m-4 to 5-membered heterocycle;
• n is 1 or 2;
• m is 0 or 1;
• and
• p is 0 or 1.